VANCOUVER, BC — May 5, 2026 — Leads & Copy — Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) announces that its wholly-owned subsidiary, Inka Health Corp., has entered into a collaborative research agreement with GlaxoSmithKline LLC (GSK) to develop methodologies for improving the transportability of oncology clinical trial results.
The goal is to make clinical evidence more relevant to real-world decision-making. The agreement will see Inka Health contribute its expertise in advanced analytics, including machine learning and causal inference methods. Inka Health will work with GSK Epidemiology and RWE experts.
The collaboration aims to develop a conceptual and methodological framework for using real-world data to support the transportability of clinical trials. The work includes a comprehensive literature review on transportability methodologies. The team will also design a structured evaluation framework and retrospective testing and validation using publicly available oncology datasets and use cases.
The project is expected to contribute to jointly authored scientific manuscripts with contributors from both Inka Health and GSK.
Rodrigo Refoios Camejo, Executive Director of RWE Science & Innovation at GSK, said there is growing interest in methodologies that can help evaluate how clinical trial findings may translate across broader patient populations and care settings. Camejo said the research can contribute to the scientific dialogue in oncology and support more rigorous approaches to understanding the applicability of clinical evidence in real-world contexts.
The initiative addresses the challenge of assessing whether clinical trial findings can be applied across diverse real-world settings. The companies say a treatment that shows positive results in a controlled clinical trial involving a narrow patient group may perform differently in broader real-world populations.
The use of real-world data can help evaluate factors that may influence outcomes. The agreement is intended to support more consistent and meaningful interpretation of trial evidence across geographies and populations.
Thomas O’ O’Shaughnessy, CEO of Onco-Innovations, said the agreement reflects the type of scientific work that can help shape the future of oncology research. He said it speaks to the relevance of the company’s capabilities in evidence generation and advanced analytics.
O’Shaughnessy said that he sees it as part of the broader vision for SynoGraph and Onco’s integrated approach to oncology innovation. He added that capabilities developed across this ecosystem can help inform smarter development pathways and support the objective of advancing IND-enabling activities.
Onco-Innovations is focused on cancer research and treatment. The company said its mission is to pursue the prevention and treatment of cancer through research and solutions.
The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
Source: Onco-Innovations Limited
